PHR Q3 2026

Q1 2027 Q4 2026 Q3 2026 Q2 2026

Earnings

Phreesia posted a mixed fiscal third quarter for the period ended October 31, 2025, beating its revenue target while falling well short on the bottom line. The healthcare technology company reported revenue of $120.33 million, up 12.7% year-over-year… Read more Phreesia posted a mixed fiscal third quarter for the period ended October 31, 2025, beating its revenue target while falling well short on the bottom line. The healthcare technology company reported revenue of $120.33 million, up 12.7% year-over-year and just ahead of the $120.03 million consensus, but earnings per share of $0.07 missed the $0.24 estimate by 71.31%, weighed in part by integration costs and the timing of its $160 million AccessOne acquisition, which closed November 12. The company did swing to GAAP net income of $4.27 million from a net loss of $14.40 million a year ago, and adjusted EBITDA nearly tripled to $29.15 million, reflecting meaningful operating leverage. Analysts maintaining buy ratings noted both companies in the healthcare technology space looked oversold relative to their growth profiles. Looking ahead, Phreesia raised and narrowed its FY2026 revenue guidance to $479 to $481 million and significantly lifted its adjusted EBITDA outlook to $99 to $101 million, while introducing FY2027 revenue guidance of $545 to $559 million, representing 14% to 16% growth.